Jazz Pharmaceuticals PLC Update on Rylaze Investor Webcast Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : This is Daniel for Jessica Fye. Maybe first, could you characterize the potential size of the market that you could unlock now that the supply issues have been addressed? And maybe in line with that, could you also characterize the market opportunity for patients with silent inactivation? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 20, 2021 / 8:30PM, JAZZ.OQ - Jazz Pharmaceuticals PLC Update on Rylaze Investor Webcast And third one would be, would the label expansion for IM dosed on Monday, Wednesday, Friday come at the same time as IV? Or in sequence? And when could that happen?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Congrats. So first, how important is it to have the additional dosing cohorts for the uptake of Rylaze, the higher doses and also the IV? What portion of patients would opt for IV versus IM? Is it just in Europe where they would opt for it or also in the U.S. potentially? And then secondly, any reason physicians would consider using Erwinaze rather than Rylaze for new patients for all the reasons you just laid out, Bruce? And can patients switch from Erwinaze to Rylaze if their mid-treatment and supply runs out for Erwinaze?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Okay. Actually, just to follow up, with respect to the higher doses, do you need to have that, you think, to have maximum uptake? Or all the patients would potentially go on the 25 milligram given that's what's available at this point?